The Outcomes of an Improved Treatment of Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease


Halyna Mykhalchyshyn


Nowadays we notice the increase of cases that combine type two diabetes mellitus, and nonalcoholic fatty liver disease. As a result, the course of disease aggravates. The pathogenesis, diagnoses and treatment of NAFLD remain unclear.

The objective: of our study is to determine the clinical efficacy of an improved therapeutic measures set in patients with type 2 diabetes and NAFLD.

Materials and methods. We’ve examined 132 patients with type 2 diabetes mellitus and NAFLD. All patients gave their consent to participate in the study. They also received all necessary nutrition and workout recommendations. We split the patients into two groups. First group patients (n=37) received antihyperglycemic drugs (metformin, gliclazide or glimepiride). Patients of the second group (n=95) additionally received DPP-4 inhibitors (saxagliptin or sitagliptin), atorvastatin, and the multiprobiotic. Patients of the second group were divided into 2 subgroups: 2A group with standard level of transaminases, and 2B group with an increased level of transaminases accordingly.

Results. Improved set of therapeutic measures revealed distinctively positive effect on the dynamics of clinical manifestation of lesions of the hepatobiliary system in patients with diabetes. There were no such changes in another group. Under the influence of complex treatment in the second group of patients, the functional state of liver improved due to a significant decrease of ALT, AST, TG and VLDL levels in the blood serum. Size of the liver decreased, liver stiffness indicators improved according to shear wave elastography data.

Conclusions. Combined therapy, which includes DPP-4 inhibitors, statins and multiperiodic is effective in the treatment of patients with type two diabetes and nonalcoholic fatty liver disease.


How to Cite
Mykhalchyshyn, H. (2021). The Outcomes of an Improved Treatment of Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Family Medicine, (5-6), 79–83.
Author Biography

Halyna Mykhalchyshyn, Bogomolets National Medical University

Halyna P. Mykhalchyshyn,

Department of Endocrinology


IDF Diabetes Atlas, 9th Edition. 2019. Available at:

Younossi ZM, Golabi P, de Avila L, Minhui PJ, Srishord M, Fukui N, Qiu Y, Burns L. Afendy A, Nader F. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. J Hepatol. 2019 Jul 4. pii: S01688278(19)30393– 9

Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology. 2017;65:2100–9.

Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–25. e716.

Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.

Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769–77.

Farrell GC, Van Rooyen D, Gan L, Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut and Liver. 2012;6:149.

Кобиляк НМ, Динник ОБ, Михальчишин ГП, Боднар ПМ. Жорсткість печінки у тварин з глютаматіндукованим ожирінням (за даними ультразвукової еластографії хвилі зміщення). Лікарська справа. 2013;3:85–9.

Боднар ПМ, Динник ОБ, Михальчишин ГП, Берегова ТВ, Кобиляк НМ, Фалалєєва ТМ, Кондро ММ. Діагностична ефективність нового ультразвукового методу оцінки жорсткості печінки – еластографії хвилі зсуву у тварин з експериментальним ожирінням. Доповіді НАН України. 2013;4: 159–66.

Bodnar PM, Dynnik OB, Mykhalchyshyn GP, Kobyliak NM, Prybytko IY., Kondro MM. Diagnosis of experimental steatohepatosis using ultrasound shear wave elastography. Current Issues in Pharmacy and Medical Sciences. 2013;26(1):109–113.